GET DAILY SIGNALSSarepta Therapeutics (SRPT) Delivers Q3 Earnings Beat and Raises Guidance
Key Takeaways
- Sarepta Therapeutics reported third-quarter 2026 earnings per share (EPS) of $0.13, beating the consensus estimate of $0.11 by $0.02.
- Total revenue came in at $381.4 million, above the analyst consensus of $353.25 million, driven by a durable exon-skipping franchise.
- Total net product revenue was approximately $324 million, split between $83 million from ELEVIDYS and $240 million from the PMO franchise.
- Management raised the low end of its 2026 total net product revenue guidance by $50 million, narrowing the range to $1.25 billion–$1.3 billion.
- The company continues to advance its DM1 and FSHD pipeline, with multiple-dose data expected in the coming weeks.
Why These Results Matter
Sarepta Therapeutics is a leader in precision genetic medicine for rare neuromuscular diseases, anchored by its Duchenne muscular dystrophy (DMD) franchise. The company's quarterly results matter because investors are watching two things closely: whether demand for ELEVIDYS, its one-time gene therapy, is stabilizing after a difficult 2025, and whether the mature exon-skipping business can keep generating the cash needed to fund an emerging pipeline in DM1 and FSHD. With a new CEO in place for roughly 90 days and the stock trading below prior-year levels, this report served as an important checkpoint on execution, cost discipline, and the credibility of management's full-year guidance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
Sarepta reported third-quarter 2026 EPS of $0.13, exceeding the analyst consensus estimate of $0.11 by $0.02. Total revenue reached $381.4 million, ahead of the $353.25 million analysts had expected. Total net product revenue was approximately $324 million, including $83 million from ELEVIDYS and $240 million from the PMO (phosphorodiamidate morpholino oligomer) exon-skipping franchise, which spans therapies such as EXONDYS 51, VYONDYS 53, and AMONDYS 45.
Operating expenses fell sharply year over year, reflecting the pipeline reprioritization and restructuring announced in mid-2025. Research and development expenses for the quarter were $82.5 million, down from $218.9 million a year earlier, largely due to the absence of a prior-year milestone payment tied to the Arrowhead collaboration. The combination of top-line strength and reduced spending supported continued non-GAAP profitability and cash generation.
On the guidance front, management raised the low end of its 2026 total net product revenue outlook by $50 million, narrowing the range to $1.25 billion–$1.3 billion. The increase was attributed to the strength of the PMO business and the stabilization of ELEVIDYS demand.
Market Reaction and Investor Sentiment
Shares of SRPT closed the regular session at $17.57, up roughly 4.7% over the prior three months but essentially flat over the trailing 12 months. Despite the earnings beat, the stock slipped about 2.1% in after-hours trading to around $17.20, suggesting investors were weighing the headline beat against lingering questions about the pace of ELEVIDYS recovery. The company has seen a mixed pattern of analyst revisions recently, reflecting ongoing debate over the durability of the gene therapy's demand and the timing of pipeline readouts.
Forward Outlook and Key Factors to Monitor
Management expects ELEVIDYS revenue in the fourth quarter to trend in line with the third quarter, with quarter-to-quarter variability inherent to a one-time gene therapy. The exon-skipping franchise is expected to remain strong, underpinning the raised full-year guidance.
The biggest near-term catalyst is the pipeline. Sarepta has said it will share multiple ascending dose data for its DM1 program (SRP-1003) and FSHD program (SRP-1001) in the coming weeks. These readouts are central to the investment case, because success could support the initiation of registrational studies for two genetically defined diseases with limited treatment options.
Investors should also monitor ELEVIDYS enrollment indicators, the continued rollout of long-term EMBARK data, and the ENDEAVOR Cohort 8 study, which evaluates a prophylactic sirolimus regimen for non-ambulatory patients. Cost discipline remains a watch item as the company balances pipeline investment against a focus on non-GAAP profitability and cash generation.
Exploring AI-Powered Screening in My Research
In my analysis of earnings-driven names like SRPT, I often turn to Tickeron’s AI Screener for a structured way to filter opportunities. It helps surface ideas based on patterns, fundamentals, and signals without replacing core fundamental work. This tool has become a useful part of my routine for narrowing down setups worth closer review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SRPT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for SRPT moved above the 200-day moving average on October 09, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on SRPT as a result. In 64 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for SRPT just turned positive on October 20, 2026. Looking at past instances where SRPT's MACD turned positive, the stock continued to rise in 29 of 46 cases over the following month. The odds of a continued upward trend are 63%.
Following a +3.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRPT advanced for three days, in 223 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 58 cases where SRPT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
SRPT moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SRPT crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
SRPT broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SRPT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.313) is normal, around the industry mean (2.904). P/E Ratio (-13.007) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (1.125) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. SRPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of treatments for life-threatening illnesses and viruses
Industry Biotechnology
Advertisement